CA
NZ
UK
AU
IND
US
Director Richard M. Martinez filed a Form 4 with the SEC on August 14, 2026, reporting the sale of 2,000 shares of First Northern Community Bancorp common stock on August 13, 2026.
Reid Dove, a director and CEO of AAA Cooper Transportation at Knight-Swift Transportation Holdings Inc., filed a statement of changes in beneficial ownership on August 14, 2026, reporting the sale of 169,154 shares of Class A Common Stock held indirectly through a foundation across …
A Form 4 filed on August 14, 2026, with the U.S. Securities and Exchange Commission discloses that Michael R. Hayden, a director of AbCellera Biologics Inc. (NASDAQ:ABCL), acquired 46,387 common shares on August 12, 2026, at a weighted-average price of $10.37 per share.
AbCellera Biologics Inc. Chief Financial Officer Andrew Booth filed a Form 4 on August 14, 2026, disclosing a purchase of 37,200 common shares of the company on that same date.
Joseph Wm. Foran, Chairman and CEO of Matador Resources Co (NYSE:MTDR), filed a Form 4 on August 14, 2026, reporting the open-market purchase of 15,000 shares of common stock across two transactions on August 12 and August 13, 2026.
A Form 4 filed on August 14, 2026, reports that Douglas R. Deason, a director of Galaxy Digital Inc. (NASDAQ:GLXY), purchased 12,000 shares of Class A Common Stock on August 12, 2026, through an entity he controls.
Guillermo Del Castillo Cacho, Energy Manager at Vesta Real Estate Corporation, S.A.B. de C.V. (NYSE:VTMX), filed a Form 4 on August 14, 2026, disclosing the sale of 10,000 ordinary shares on August 12, 2026.
Presidio Production Company filed a Form 8-K with the U.S. Securities and Exchange Commission on August 14, 2026, disclosing the issuance of a press release and earnings call transcript covering its financial results for the quarter ended June 30, 2026.
Valvoline Inc. filed a Form 8-K with the SEC on August 13, 2026, disclosing the pricing of a $600 million aggregate principal amount of 6.125% senior notes due 2034, upsized from an initially announced $500 million offering.
Eikon Therapeutics, Inc. filed a Form 8-K with the SEC on August 14, 2026, disclosing that the company updated its corporate presentation on August 13, 2026, under Regulation FD.
Please wait processing your request...